Albert Bourla explains his divestiture of consumer healthcare by arguing that a corporation's role is not to hedge risk—that's for investors. Instead, companies must cultivate a focused culture to become exceptionally good in a few core areas, which for Pfizer is innovative science.
Albert Bourla identifies Chinese pharmaceutical companies as a paradigm-shifting threat, not an incremental one. He quantifies their advantage as operating with "half the cost and three times the speed," demanding a fundamental transformation of Western pharma companies within five years to remain competitive.
In response to the competitive threat from Chinese firms operating at a different speed and cost, Pfizer's CEO states the only viable path forward is a radical transformation through technology, specifically citing AI. The goal is to fundamentally change processes to match the new competitive landscape.
After a major internal scientific setback in the obesity space, Pfizer acquired a company with a promising drug. This strategy wasn't just about buying a product, but acquiring a missing scientific asset to plug into its existing world-class commercial and manufacturing infrastructure, thereby capitalizing on its established strengths.